Immatics (IMTX)
(Delayed Data from NSDQ)
$10.35 USD
-0.17 (-1.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.33 -0.02 (-0.19%) 5:12 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.35 USD
-0.17 (-1.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.33 -0.02 (-0.19%) 5:12 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)
by Zacks Equity Research
Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
by Zacks Equity Research
The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%
by Zacks Equity Research
The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -2.94% and 28.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 0% and 75.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -8.33% and 41.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PhenomeX Inc. (CELL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -3.13% and 15.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immatics (IMTX) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 81.5% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -276.92% and 56.96%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
by Zacks Equity Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?